Tuhura Biosciences Publishes Corporate Presentation on Overcoming Resistance to Cancer Immunotherapy

Reuters03-07

Tuhura Biosciences Publishes Corporate Presentation on Overcoming Resistance to Cancer Immunotherapy

Tuhura Biosciences Inc. released a corporate presentation outlining its immuno-oncology pipeline focused on addressing resistance to cancer immunotherapies. The deck highlights IFx-2.0, a tumor-targeted plasmid DNA therapy being evaluated in a Phase 3 accelerated approval study in first-line advanced or metastatic Merkel cell carcinoma in combination with pembrolizumab, with overall response rate as the primary endpoint and progression-free survival as a key secondary endpoint. The presentation also describes TBS-2025, a VISTA-inhibiting monoclonal antibody planned for a Phase 2 study in relapsed or refractory NPM1-mutant acute myeloid leukemia in combination with a menin inhibitor, and an immune-modulating bi-specific antibody-drug conjugate program targeting myeloid-derived suppressor cells, with proof-of-concept work planned in AML. You can access the full presentation through the link below. https://tuhurabio.com

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617631086?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-07 00:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617631086","market":"us","top_or_hot":-1,"title":"Tuhura Biosciences Publishes Corporate Presentation on Overcoming Resistance to Cancer Immunotherapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tuhura Biosciences Publishes Corporate Presentation on Overcoming Resistance to Cancer Immunotherapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tuhura Biosciences Inc. released a corporate presentation outlining its immuno-oncology pipeline focused on addressing resistance to cancer immunotherapies. The deck highlights IFx-2.0, a tumor-targeted plasmid DNA therapy being evaluated in a Phase 3 accelerated approval study in first-line advanced or metastatic Merkel cell carcinoma in combination with pembrolizumab, with overall response rate as the primary endpoint and progression-free survival as a key secondary endpoint. The presentation also describes TBS-2025, a VISTA-inhibiting monoclonal antibody planned for a Phase 2 study in relapsed or refractory NPM1-mutant acute myeloid leukemia in combination with a menin inhibitor, and an immune-modulating bi-specific antibody-drug conjugate program targeting myeloid-derived suppressor cells, with proof-of-concept work planned in AML. You can access the full presentation through the link below. https://tuhurabio.com\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tuhura Biosciences Publishes Corporate Presentation on Overcoming Resistance to Cancer Immunotherapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTuhura Biosciences Publishes Corporate Presentation on Overcoming Resistance to Cancer Immunotherapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-07 00:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tuhura Biosciences Publishes Corporate Presentation on Overcoming Resistance to Cancer Immunotherapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tuhura Biosciences Inc. released a corporate presentation outlining its immuno-oncology pipeline focused on addressing resistance to cancer immunotherapies. The deck highlights IFx-2.0, a tumor-targeted plasmid DNA therapy being evaluated in a Phase 3 accelerated approval study in first-line advanced or metastatic Merkel cell carcinoma in combination with pembrolizumab, with overall response rate as the primary endpoint and progression-free survival as a key secondary endpoint. The presentation also describes TBS-2025, a VISTA-inhibiting monoclonal antibody planned for a Phase 2 study in relapsed or refractory NPM1-mutant acute myeloid leukemia in combination with a menin inhibitor, and an immune-modulating bi-specific antibody-drug conjugate program targeting myeloid-derived suppressor cells, with proof-of-concept work planned in AML. You can access the full presentation through the link below. https://tuhurabio.com\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HURA","symbol_name":"TuHURA Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL8P6FLt:1","article_id":"2617631086","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617631086","pubTimestamp":1772815649,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HURA":"TuHURA Biosciences, Inc.","BK4139":"生物科技"},"translate_title":"Tuhura Biosciences发布关于克服癌症免疫疗法耐药性的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HURA":0.9},"content_text":"Tuhura Biosciences Publishes Corporate Presentation on Overcoming Resistance to Cancer Immunotherapy\n    \n\n        Tuhura Biosciences Inc. released a corporate presentation outlining its immuno-oncology pipeline focused on addressing resistance to cancer immunotherapies. The deck highlights IFx-2.0, a tumor-targeted plasmid DNA therapy being evaluated in a Phase 3 accelerated approval study in first-line advanced or metastatic Merkel cell carcinoma in combination with pembrolizumab, with overall response rate as the primary endpoint and progression-free survival as a key secondary endpoint. The presentation also describes TBS-2025, a VISTA-inhibiting monoclonal antibody planned for a Phase 2 study in relapsed or refractory NPM1-mutant acute myeloid leukemia in combination with a menin inhibitor, and an immune-modulating bi-specific antibody-drug conjugate program targeting myeloid-derived suppressor cells, with proof-of-concept work planned in AML. You can access the full presentation through the link below. https://tuhurabio.com\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617631086","isCrawlerRequest":true}